Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R. Brahmer, John A. Thompson, Christina Lacchetti et al.|Journal of Clinical Oncology|2018Cited by 3.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 MutationsDavid M. Hyman, José Baselga, Igor Puzanov et al.|New England Journal of Medicine|2015Cited by 1.7k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upArndt Vogel, Erika Martinelli, Andrés Cervantes et al.|Annals of Oncology|2018Cited by 1.1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisMustafa Suker, Bas Groot Koerkamp, Berend R. Beumer et al.|The Lancet Oncology|2016Cited by 914
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialYolanda Barbáchano, Ian Chau, David Cunningham et al.|The Lancet Oncology|2013Cited by 728